BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

BiomX (NYSE American: PHGE) announced that CEO Jonathan Solomon will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8th, 2025, from 4:30 - 5:00 PM ET at the Lotte New York Palace Hotel in New York City.

The presentation, titled "Phage Therapy: A Novel Approach to Chronic Diabetic Foot Infections," will highlight the positive topline results from the company's Phase 2 trial of BX211 for treating Diabetic Foot Osteomyelitis (DFO). Investors can request one-on-one meetings through H.C. Wainwright representatives.

Presentation to Focus on Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

NESS ZIONA, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE), a clinical-stage company advancing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that Jonathan Solomon, the Company’s Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference taking place on September 7-9, 2025, at the Lotte New York Palace Hotel in New York City. 

The presentation, titled "Phage Therapy: A Novel Approach to Chronic Diabetic Foot Infections," will take place on September 8^th from 4:30 - 5:00 PM ET. The presentation will focus on positive topline results from the Company's Phase 2 trial evaluating BX211 for the treatment of DFO.

Investors attending the event may request a one-on-one meeting with BiomX through their H.C. Wainwright representative or e-mail meetings@hcwco.com.

About BX211
BX211 is a phage treatment for the treatment of DFO associated with S. aureus. DFO is a bacterial infection of the bone that usually develops from an infected foot ulcer and is a leading cause of amputation in patients with diabetes. In March 2025, BiomX announced positive topline results from the Phase 2 trial in which BX211 was demonstrated to be safe and well-tolerated and patients receiving BX211 exhibited statistically significant¹ and sustained reduction of ulcer size (PAR)(p = 0.046 at week 12; p=0.052 at week 13), with a separation from placebo starting at week 7 and a difference greater than 40% by week 10. In addition, BX211 also produced statistically significant¹ improvements in both ulcer depth at week 13 (in patients with ulcer depth defined as bone at baseline, ulcer depth was classified according to deepest tissue involved as measured by swab) (p=0.048), and in reducing the expansion of ulcer area (p=0.017). Over the 12-week treatment period, all patients (treatment and placebo) were treated in accordance with standard of care, including with systemic antibiotic therapy as appropriate. BiomX is currently planning a registrational trial, pending discussions and feedback from the Food and Drug Administration (FDA).

About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.

Safe Harbor
This press release contains express or implied “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. For example, when BiomX refers to its anticipated timing of its future clinical trials as well as the design thereof, expected discussions with the FDA and results thereof, and the potential of its candidates to address the substantial unmet needs of patients with chronic diseases, it is using forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of BiomX’s control. These risks and uncertainties include, but are not limited to, changes in applicable laws or regulations; the possibility that BiomX may be adversely affected by other economic, business, and/or competitive factors, including risks inherent in pharmaceutical research and development, such as: adverse results in BiomX’s drug discovery, preclinical and clinical development activities, the risk that the results of preclinical studies and early clinical trials may not be replicated in later clinical trials, BiomX’s ability to enroll patients in its clinical trials, and the risk that any of its clinical trials may not commence, continue or be completed on time, or at all; decisions made by the FDA and other regulatory authorities; decisions made by investigational review boards at clinical trial sites and publication review bodies with respect to BiomX’s development candidates; BiomX’s ability to obtain, maintain and enforce intellectual property rights for its platform and development candidates; its potential dependence on collaboration partners; competition; uncertainties as to the sufficiency of BiomX’s cash resources to fund its planned activities for the periods anticipated and BiomX’s ability to manage unplanned cash requirements; and general economic and market conditions. Therefore, investors should not rely on any of these forward-looking statements and should review the risks and uncertainties described under the caption “Risk Factors” in BiomX’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 25, 2025, and additional disclosures BiomX makes in its other filings with the SEC, which are available on the SEC’s website at www.sec.gov. Forward-looking statements are made as of the date of this press release, and except as provided by law BiomX expressly disclaims any obligation or undertaking to update forward-looking statements.

Contacts:

BiomX, Inc.
Ben Cohen
Head Corporate Communications
benc@biomx.com

¹ All p-values described in this release are non-adjusted

FAQ

When is BiomX (PHGE) presenting at the H.C. Wainwright Conference 2025?

BiomX CEO Jonathan Solomon will present on September 8th, 2025, from 4:30 - 5:00 PM ET at the Lotte New York Palace Hotel in New York City.

What will BiomX (PHGE) discuss at the H.C. Wainwright Conference?

The presentation will focus on positive topline results from the Phase 2 trial of BX211 for treating Diabetic Foot Osteomyelitis (DFO), titled 'Phage Therapy: A Novel Approach to Chronic Diabetic Foot Infections.'

How can investors meet with BiomX management at the H.C. Wainwright Conference?

Investors can request one-on-one meetings through their H.C. Wainwright representative or by emailing meetings@hcwco.com.

What is BiomX's (PHGE) main therapeutic focus?

BiomX is a clinical-stage company developing natural and engineered phage therapies that target specific pathogenic bacteria.